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Abstract 
Interdigitating dendritic cell sarcoma is an
extremely  rare  cancer  that  lacks  a  standard
treatment  approach.  We  report  on  a  patient
who was surgically resected and remains dis-
ease-free. The tumor was assessed for drug-
gable  targets  using  immunohistochemical
staining to identify potential agents that could
be used in the event of disease recurrence. 
Case Report
A 25-year-old woman presented with a soli-
tary enlarged right axillary lymph node. Prior
medical  history  includes  hyperreninemic
hypertension, without an identified pathologic
lesion, requiring angiotensin receptor blockade
medication one year before the cancer diagno-
sis, and a sinus infection requiring antibiotic
therapy immediately before the cancer presen-
tation. The patient initially noted a nontender
swelling under her right axilla and sought fur-
ther  medical  evaluation.  Upon  completion  of
antibiotics for the sinus infection, the patient
underwent an ultrasound and excisional biopsy
of a 2ﾥ1 cm enlarged right axillary lymph node
with  clear  margins.  Patient’s  family  history
negative for blood disorders or malignancy and
she denied tobacco or alcohol use. 
Figure  1  shows  the  tumor  stained  with
hematoxylin  and  eosin  (H&E).  Additional
immunohistochemistry  staining  (IHC)  was
performed. The tumor specimen was strongly
positive for S100 in majority of cells, MelanA
negative, and smooth muscle actin was mod-
erately positive in the majority of tumor cells.
A bone marrow biopsy revealed normocellular
marrow  with  adequate  trilineage  hemato -
poiesis, and markedly decreased iron stain-
ing; normal karyotype, 46 XX. Flow cytometry
revealed no monoclonality, evidence of lym-
phoma or leukemia. The final pathologic diag-
nosis was interdigitating dendritic cell sarco-
ma (IDCS) after independent confirmation at
a reference pathology laboratory (performed
by RJP). 
[18F]-2-fluoro-deoxy-D-glucose (FDG) com-
puted  tomography  (PET/CT)  revealed  low
uptake of FDG tracer in right axilla in area of
excision. No adenopathy was visualized. The
patient  was  followed  conservatively  without
receiving adjuvant chemotherapy or radiother-
apy.
1Follow-up PET/CT scans at 4, 7, 11, 18, and
24  months  showed  no  evidence  of  disease
recurrence and physical exam was stable and
remained unremarkable. She is now followed
conservatively on an annual basis with physi-
cal examination and imaging. 
Using  a  molecular  profiling  approach,  we
assessed her tumor for potential treatment tar-
gets to see if there would be conventional
2 or
investigational agents under development that
could be used to treat her cancer in the event
of disease relapse. Only formalin-fixed, paraf-
fin-embedded (FFPE) tumor was available. IHC
molecular characterization for treatment tar-
gets was performed (TargetNow® test, Caris
Life Sciences, Phoenix, AZ, USA)
2 with poten-
tial treatment options shown in Table 1. The
tumor was positive for SPARC, secreted pro-
tein  acid  rich  in  cysteine  (Figure  2),  and
HSP90  (Figure  3)  and  negative  for  PDGFR,
MSH1, MSH2, c-kit, Her2/Neu, P-glycoprotein,
ER, PR, Androgen Receptor, CD25, and CD52.
Of note, the tumor sample was also sent for
commercial  testing  for  carcinoma  unknown
primary (CUP) testing to see if it had a molec-
ular signature in common with up to 39 cancer
types  (Quest  Diagnostics  Nichols  Institute,
San Juan Capistrano, CA, USA). The sample
was run twice, and remained “unclassifiable”
amongst the list of 39 cancer genomic signa-
tures. The closest matches for this patient’s
tumor, albeit with low probability, were B-, T-,
and Hodgkin’s lymphoma, small cell lung can-
cer, and melanoma.
Discussion
Interdigitating  dendritic  cells  are  potent
antigen presenting cells found in T-cell areas
of  peripheral  lymphoid  tissue.
3 IDCS  is  an
extremely rare neoplasm that can mimic other
primary and metastatic spindle cell neoplasms
of lymph nodes. Characterized by S100, CD68,
and  CD45RB  staining,  IDCS  often  presents
with metastasis and portends a poor progno-
sis.
3 Within localized disease treated with sur-
gery  alone,  approximately  50%  remain  dis-
ease-free  with  a  median  follow  up  of  12
months (range 2 months to 19 years).
1 In con-
trast,  with  advanced  IDCS,  survival  rarely
exceeds 12 months, despite various treatment
modalities including surgical excision, multi-
agent  systemic  chemotherapy  and/or  radio-
therapy.
3 Here we present molecular character-
ization of a case of IDCS with oncogenes iden-
tified as potential targets for treatment. 
One of the targets identified was SPARC, also
known as osteonectin. This protein belongs to a
family of matricellular proteins and there has
been growing evidence of its role in a variety of
cancers.
4 High levels of SPARC could be target-
ed by nanoparticle albumin-bound (NAB)-pacli-
taxel, approved for use in patients with metasta-
tic  breast  cancer  and  currently  undergoing
Phase III trials for patients with pancreatic can-
cer (www.clinicaltrials.gov). A few studies indi-
cate that SPARC over-expression improves the
response to the anticancer drug, nab-paclitaxel.
It is thought that improved response is related
to the high affinity of albumin to SPARC, thus
will potentiate nab-paclitaxel to specifically tar-
get SPARC expressing cells.
5,6 The other target
identified was HSP90 (heat-shock protein 90).
This is an evolutionarily conserved chaperone
molecule that is involved in the folding, stabi-
lization,  activation  and  assembly  of  various
client proteins.
7Cancer cells often require high-
er HSP90 activity to maintain their malignant
potential, thus HSP90 has emerged as a promis-
ing therapeutic target. Indeed, there are several
intravenous  and  oral  formulations  of  HSP90
inhibitors in various phases of drug develop-
ment  (www.clinicaltrials.gov),  though  no
HSP90 therapeutics are currently commercially
approved for cancer treatment at this time. 
In summary, this patient had localized IDCS,
treated with surgical excision, and remained
disease  free  at  at  least  24  months  without
requiring  any  adjuvant  therapy.  IDCS  is  an
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temic therapy. This tumor could not be classi-
fied into any of 39 tumor types on a CUP test-
ing. Lastly, we attempted to characterize drug-
gable  targets  using  IHC  profiling  and  found
SPARC  and  HSP90  as  potential  targets  with
either commercially available or investigation-
al agents under study. Molecular characteriza-
tion of rare cancers may help enable investiga-
tors to identify a potential Achilles’ heal that
could improve the outcomes for patients with
exceedingly uncommon malignancies.
8
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Case Report
Table 1. Immunohistochemistry staining analysis-interdigitating dendritic cell sarcoma.
Positive IHC staining Conclusions Specificity Intensity % Potential agent to be tried
SPARC Positive  Specific 3+ 40 Paclitaxel-albumin bound
HSP90 Positive Specific 2+ 70 HSP90 inhibitor (e.g. CNF2024, SNX5422, IPI-504, or a geldanomycin derivative)
Other IHC proteins tested but not considered targets due to absence of 2+ IHC in ≥30% of tumor cells include: PDGFR, MSH1, MSH2, c-kit, Her2/Neu, P-glycoprotein, ER, PR, Androgen Receptor, CD25 and CD52.
IHC, immunohistochemistry staining. 
Figure 1. Interdigitating dendritic cell sar-
coma  tumor  Specimen-hematoxylin  and
eosin  stain  at  10X  magnfication.  Higher
magnification (40X) is displayed in lower
right quadrant.
Figure 2. HSP90 paraffin section immuno-
histochemistry demonstrating 2+ cytoplas-
mic  reactivity  in  interdigitating  dendritic
cell  sarcoma cells.  Higher  magnification
(40X) is displayed in lower right quadrant.
Figure  3.  SPARC  Polyclonal  paraffin  sec-
tion immunohistochemistry demonstrating
3+ cytoplasmic reactivity in interdigitating
dendritic cell sarcoma cells. Higher magni-
fication (40X) is displayed in lower right
quadrant.
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